Immunogenicity and safety of the 9-valent human papillomavirus vaccine in Chinese females 9–45 years of age: A phase 3 open-label study
Huakun Lv, Shenyu Wang, Zhenzhen Liang, Wei Yu, Chuanfu Yan, Ying-ping Chen, Xiaosong Hu, Rong Fu, Minghuan Zheng, Thomas Group, Alain Luxembourg, Xueyan Liao, Zhiping Chen
Topics & Concepts
SeroconversionMedicineImmunogenicityAdverse effectVaccinationAntibody titerPopulationTiterAntibodyInternal medicineImmunologyEnvironmental healthCervical Cancer and HPV ResearchHead and Neck Cancer StudiesImmunotherapy and Immune Responses